In Conversation With… Tonya Winders
"For more than 20 years, we've had monoclonal antibodies for asthma, yet only one in five eligible patients are on them. And in more than 80 countries, there isn’t a single biologic available." The ...
The Trials Driving the Next Wave of Steroid-Sparing Innovation
A wave of clinical trial results using the STOX® Suite of clinical outcome assessments (COAs) in a range of diseases will soon reach the shore, helping to deliver new therapeutic options for ...
In Conversation With… Joyce Kullman
“Imagine how many lives could be saved if we spent as much energy on rare disease awareness and education as we do on celebrity culture.” Patient advocacy groups (PAGs) are critical in bridging the ...
Promising Monoclonal Antibody Offers New Steroid-Sparing Hope for IgG4-RD
Results from the Phase 3 MITIGATE trial of a biologic called inebilizumab have raised hopes the tide may be turning in the hunt for an alternative treatment to steroids for IgG4-related disease ...
The Digital Tool Helping Neurologists Be Patient-Loving Physicians
Myasthenia gravis is a rare immune-mediated disorder (affecting less than 100,000 patients in the US) in which the immune system mistakenly targets nerves or muscles. Historically, myasthenia gravis ...
Curious about the true cost of steroid-toxicity?
Download our infographic today
